These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

698 related articles for article (PubMed ID: 30150001)

  • 41. A review for clinicians: Prostate cancer and the antineoplastic properties of metformin.
    Hankinson SJ; Fam M; Patel NN
    Urol Oncol; 2017 Jan; 35(1):21-29. PubMed ID: 27836248
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metformin-like antidiabetic, cardio-protective and non-glycemic effects of naringenin: Molecular and pharmacological insights.
    Nyane NA; Tlaila TB; Malefane TG; Ndwandwe DE; Owira PMO
    Eur J Pharmacol; 2017 May; 803():103-111. PubMed ID: 28322845
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
    Ben Sahra I; Le Marchand-Brustel Y; Tanti JF; Bost F
    Mol Cancer Ther; 2010 May; 9(5):1092-9. PubMed ID: 20442309
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport.
    Horakova O; Kroupova P; Bardova K; Buresova J; Janovska P; Kopecky J; Rossmeisl M
    Sci Rep; 2019 Apr; 9(1):6156. PubMed ID: 30992489
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metformin; an old antidiabetic drug with new potentials in bone disorders.
    Bahrambeigi S; Yousefi B; Rahimi M; Shafiei-Irannejad V
    Biomed Pharmacother; 2019 Jan; 109():1593-1601. PubMed ID: 30551413
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase.
    Guo Q; Liu Z; Jiang L; Liu M; Ma J; Yang C; Han L; Nan K; Liang X
    Mol Med Rep; 2016 Mar; 13(3):2590-6. PubMed ID: 26847819
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of AMPK/mTOR signaling pathway in anticancer activity of metformin.
    Chomanicova N; Gazova A; Adamickova A; Valaskova S; Kyselovic J
    Physiol Res; 2021 Aug; 70(4):501-508. PubMed ID: 34062070
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metformin induces renal medullary interstitial cell apoptosis in type 2 diabetic mice.
    Zheng S; Liu J; Han Q; Huang S; Su W; Fu J; Jia X; Du S; Zhou Y; Zhang X; Guan Y
    J Diabetes; 2014 Mar; 6(2):132-46. PubMed ID: 24405721
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metformin and Its Benefits for Various Diseases.
    Lv Z; Guo Y
    Front Endocrinol (Lausanne); 2020; 11():191. PubMed ID: 32425881
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metformin Activates AMPK through the Lysosomal Pathway.
    Zhang CS; Li M; Ma T; Zong Y; Cui J; Feng JW; Wu YQ; Lin SY; Lin SC
    Cell Metab; 2016 Oct; 24(4):521-522. PubMed ID: 27732831
    [No Abstract]   [Full Text] [Related]  

  • 51. Mechanism and application of metformin in kidney diseases: An update.
    Song A; Zhang C; Meng X
    Biomed Pharmacother; 2021 Jun; 138():111454. PubMed ID: 33714781
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
    Ling S; Xie H; Yang F; Shan Q; Dai H; Zhuo J; Wei X; Song P; Zhou L; Xu X; Zheng S
    J Hematol Oncol; 2017 Feb; 10(1):59. PubMed ID: 28241849
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The development and benefits of metformin in various diseases.
    Dong Y; Qi Y; Jiang H; Mi T; Zhang Y; Peng C; Li W; Zhang Y; Zhou Y; Zang Y; Li J
    Front Med; 2023 Jun; 17(3):388-431. PubMed ID: 37402952
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metformin: its emerging role in oncology.
    Micic D; Cvijovic G; Trajkovic V; Duntas LH; Polovina S
    Hormones (Athens); 2011; 10(1):5-15. PubMed ID: 21349801
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect.
    Saisho Y
    Endocr Metab Immune Disord Drug Targets; 2015; 15(3):196-205. PubMed ID: 25772174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
    Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
    Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
    [TBL] [Abstract][Full Text] [Related]  

  • 57. mTORC1 inhibitors rapamycin and metformin affect cardiovascular markers differentially in ZDF rats.
    Nistala R; Raja A; Pulakat L
    Can J Physiol Pharmacol; 2017 Mar; 95(3):281-287. PubMed ID: 28177677
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3,4,5-(PO4)3 in muscle of diabetic subjects.
    Luna V; Casauban L; Sajan MP; Gomez-Daspet J; Powe JL; Miura A; Rivas J; Standaert ML; Farese RV
    Diabetologia; 2006 Feb; 49(2):375-82. PubMed ID: 16395615
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Metformin and malignant neoplasms: a possible mechanism of antitumor action and prospects for use in practice].
    Kuznetsov KO; Safina ER; Gaimakova DV; Frolova YS; Oganesyan IY; Sadertdinova AG; Nazmieva KA; Islamgulov AH; Karimova AR; Galimova AM; Rizvanova EV
    Probl Endokrinol (Mosk); 2022 Jul; 68(5):45-55. PubMed ID: 36337018
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A New Role for an Old Drug: Metformin Targets MicroRNAs in Treating Diabetes and Cancer.
    Zhou JY; Xu B; Li L
    Drug Dev Res; 2015 Sep; 76(6):263-9. PubMed ID: 26936407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.